Related Experiment Video
Updated: Jul 10, 2026
07:24
Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing
Published on: February 10, 2023
Rapid screening for potentially relevant polymorphisms in the human fatty acid amide hydrolase gene using
Alexandra Doehring1, Gerd Geisslinger, Jörn Lötsch
1Pharmazentrum Frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe-University, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany.
Prostaglandins & Other Lipid Mediators
|November 10, 2007
Summary
Researchers developed new assays to quickly identify genetic variations in fatty acid amide hydrolase (FAAH). These tools will help study how FAAH gene variants influence conditions like pain and addiction.
Area of Science:
- Pharmacogenomics
- Molecular Biology
- Human Genetics
Background:
- Fatty acid amides, like anandamide, are lipid transmitters involved in inflammation.
- Fatty acid amide hydrolase (FAAH) rapidly degrades these compounds.
- Genetic variants in FAAH are linked to pain and addiction, but their clinical significance is unclear.
Purpose of the Study:
- To develop high-throughput screening assays for fatty acid amide hydrolase (FAAH) polymorphisms.
- To facilitate research into the clinical roles of FAAH genetic variants.
Main Methods:
- Developed six Pyrosequencing assays for frequent and functionally associated FAAH polymorphisms (rs932816, rs4141964, rs324420, rs324419, rs2295633, rs12029329).
- Validated assays in DNA samples from 350 healthy Caucasians using conventional sequencing for verification.
Main Results:
- Pyrosequencing assays accurately identified all six FAAH polymorphisms in 350 samples.
- Observed allele frequencies were consistent with Hardy-Weinberg equilibrium.
- Identified high linkage disequilibrium among most SNPs, forming a single haploblock.
Conclusions:
- Developed rapid and reliable Pyrosequencing assays for detecting FAAH genotypes.
- These assays can advance the investigation of genetic associations with FAAH function and clinical outcomes.
